Eterna Therapeutics Net Income

Eterna Therapeutics posts a net income of $-11M as of March 2026. That compares with $-46M in the prior-year period — up 75.3% year over year. That is below the Telecommunications sector average of $280B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Eterna Therapeutics's net income was $-46M. The latest reading is $-11M — a 75.3% year-over-year increase (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

For Telecommunications stocks, a net income near $280B is typical. Eterna Therapeutics's $-11M is lower that level. That is roughly 100.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Net Income is one piece of Eterna Therapeutics's financial statement story. At $-11M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for ERNA's net income usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $280B), and (3) consistency with growth and profitability. This page covers the first two; Eterna Therapeutics's other metric pages and overview cover the third.